OpenURL Connection Search

Select item for more details and to access through your institution.

Hematological Effects of Intermittent 2-Hour Infusions of Cladribine in Multiple Sclerosis Patients: A Comparison of 2 Dosage Patterns.
Published in:
International Journal of Hematology, 2001, v. 74, n. 4, p. 421, doi. 10.1007/BF02982086
By:
- Grieb, Paweł;
- Kamienowski, Jerzy;
- Janisz, Monika;
- Kuśnierczyk, Piotr;
- Kawiak, Jerzy;
- Hoser, Grazyna;
- Chrapusta, Stanisław
Publication type:
Article
FENOTYP ACETYLACJI U CHORYCH NA ZESPOŁY NEUROLOGICZNE I PSYCHIATRYCZNE.
Published in:
Problemy Terapii Monitorowanej, 2010, v. 21, n. 3, p. 143
By:
- MILEJSKI, PIOTR;
- NIEWIŃSKI, PRZEMYSŁAW;
- ORZECHOWSKA-JUZWENKO, KRYSTYNA;
- KAMIENOWSKI, JERZY;
- HOROCH, EWA;
- KIEJNA, ANDRZEJ;
- BESZŁEJ, ALEKSANDER JERZY;
- HURKACZ, MAGDALENA
Publication type:
Article
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Published in:
Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 48, doi. 10.1111/jns.12302
By:
- Merkies, Ingemar S.J.;
- van Schaik, Ivo N.;
- Léger, Jean‐Marc;
- Bril, Vera;
- Geloven, Nan;
- Hartung, Hans‐Peter;
- Lewis, Richard A.;
- Sobue, Gen;
- Lawo, John‐Philip;
- Durn, Billie L.;
- Cornblath, David R.;
- De Bleecker, Jan L.;
- Sommer, Claudia;
- Robberecht, Wim;
- Saarela, Mika;
- Kamienowski, Jerzy;
- Stelmasiak, Zbigniew;
- Tackenberg, Björn;
- Mielke, Orell;
- Sabet, A.
Publication type:
Article
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Published in:
Journal of the Peripheral Nervous System, 2017, v. 22, n. 2, p. 149, doi. 10.1111/jns.12204
By:
- Merkies, Ingemar S. J.;
- Lawo, John‐Philip;
- Edelman, Jonathan M.;
- De Bleecker, Jan L.;
- Sommer, Claudia;
- Robberecht, Wim;
- Saarela, Mika;
- Kamienowski, Jerzy;
- Stelmasiak, Zbigniew;
- Mielke, Orell;
- Tackenberg, Björn;
- Léger, Jean‐Marc;
- De Bleecker, J. L.;
- Robberecht, W.;
- Saarela, M.;
- Franques, J.;
- Léger, J.‐M.;
- Juntas Morales, R.;
- Sommer, C.;
- Nguento, A.
Publication type:
Article
Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
Published in:
2013
By:
- Léger, Jean-Marc;
- De Bleecker, Jan L.;
- Sommer, Claudia;
- Robberecht, Wim;
- Saarela, Mika;
- Kamienowski, Jerzy;
- Stelmasiak, Zbigniew;
- Mielke, Orell;
- Tackenberg, Björn;
- Shebl, Amgad;
- Bauhofer, Artur;
- Zenker, Othmar;
- Merkies, Ingemar S. J.
Publication type:
Journal Article
Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Published in:
Journal of the Peripheral Nervous System, 2013, v. 18, n. 2, p. 130, doi. 10.1111/jns5.12017
By:
- Léger, Jean‐Marc;
- De Bleecker, Jan L.;
- Sommer, Claudia;
- Robberecht, Wim;
- Saarela, Mika;
- Kamienowski, Jerzy;
- Stelmasiak, Zbigniew;
- Mielke, Orell;
- Tackenberg, Björn;
- Shebl, Amgad;
- Bauhofer, Artur;
- Zenker, Othmar;
- Merkies, Ingemar S. J.
Publication type:
Article

Found: 6

Hematological Effects of Intermittent 2-Hour Infusions of Cladribine in Multiple Sclerosis Patients: A Comparison of 2 Dosage Patterns.

FENOTYP ACETYLACJI U CHORYCH NA ZESPOŁY NEUROLOGICZNE I PSYCHIATRYCZNE.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.

Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

Efficacy and safety of Privigen<sup>®</sup> in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).